Edition:
United States

Bison Capital Acquisition Corp (BCAC.OQ)

BCAC.OQ on NASDAQ Stock Exchange Capital Market

10.32USD
18 Jan 2019
Change (% chg)

$-0.09 (-0.86%)
Prev Close
$10.41
Open
$9.93
Day's High
$10.48
Day's Low
$9.93
Volume
1,200
Avg. Vol
6,641
52-wk High
$10.54
52-wk Low
$9.84

Latest Key Developments (Source: Significant Developments)

Bison Capital Acquisition Reports Terms of Xynomic deal termination
Thursday, 13 Sep 2018 06:13am EDT 

Sept 13 (Reuters) - Bison Capital Acquisition Corp ::BISON CAPITAL ACQUISITION - XYNOMIC WILL BE OBLIGATED TO PAY CO'S SPONSOR A $4.5 MILLION TERMINATION FEE IF DEAL TERMINATED UNDER CERTAIN CONDITIONS.  Full Article

Bison Capital Acquisition, Xynomic Pharmaceuticals Sign Definitive Merger Agreement
Wednesday, 12 Sep 2018 09:49pm EDT 

Sept 12 (Reuters) - Bison Capital Acquisition Corp ::Bison Capital Acquisition Corp. AND XYNOMIC PHARMACEUTICALS, INC. ANNOUNCE SIGNING OF DEFINITIVE MERGER AGREEMENT.UPON COMPLETION OF MERGER, XYNOMIC WILL BECOME A WHOLLY-OWNED SUBSIDIARY AND OPERATING BUSINESS OF BCAC.BISON CAPITAL ACQUISITION-AGGREGATE MERGER CONSIDERATION WILL CONSIST OF CLOSING CONSIDERATION OF $350 MILLION IN BCAC SHARES, SUBJECT TO CERTAIN ADJUSTMENTS.UPON COMPLETION OF MERGER BCAC WILL CHANGE ITS NAME TO "XYNOMIC PHARMACEUTICALS HOLDINGS, INC.UNDER TERMS OF AGREEMENT, CO WILL RE-DOMESTICATE FROM BRITISH VIRGIN ISLANDS TO DELAWARE PRIOR TO MERGER.BISON CAPITAL ACQUISITION- AGGREGATE MERGER CONSIDERATION WILL CONSIST OF EARNOUT CONSIDERATION OF ADDITIONAL $100 MILLION IN BCAC SHARES.MERGER CONSIDERATION WILL BE PAYABLE ENTIRELY IN COMMON STOCK OF BCAC AT A VALUE OF $10.15 PER SHARE.EXECUTIVES OF XYNOMIC ARE EXPECTED TO REMAIN AS EXECUTIVES OF COMBINED COMPANY.  Full Article

No consensus analysis data available.